We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

111 hedge funds and large institutions have $721M invested in NxStage Medical Inc. in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,368% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $60K

45% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 29

14% more funds holding in top 10

Funds holding in top 10: 78 (+1)

3% less funds holding

Funds holding: 115111 (-4)

7% less capital invested

Capital invested by funds: $775M → $721M (-$54M)

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

Holders
111
Holders Change
-4
Holders Change %
-3.48%
% of All Funds
3.22%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.23%
New
13
Increased
42
Reduced
29
Closed
17
Calls
$1.48M
Puts
$60K
Net Calls
+$1.42M
Net Calls Change
-$3.08M
Name Holding Trade Value Shares
Change
Change in
Stake
N
26
Nuveen
North Carolina
$5.5M -$1.57M -116,343 -22%
DCM
27
DAFNA Capital Management
California
$5.04M
CAD
28
Craig A. Drill
$4.95M -$1.29M -95,900 -20%
PP
29
Paloma Partners
Connecticut
$4.82M
FLAM
30
First Light Asset Management
Minnesota
$4.54M +$2.16M +160,097 +86%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$4.26M +$224K +16,604 +5%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$4.11M +$263K +19,562 +7%
WMSA
33
Weiss Multi-Strategy Advisers
New York
$4.07M -$337K -25,000 -7%
TCIM
34
TIAA CREF Investment Management
New York
$3.04M -$44.4K -3,297 -1%
HPCM
35
High Pointe Capital Management
Illinois
$2.81M
ERSOT
36
Employees Retirement System of Texas
Texas
$2.6M
CCP
37
Clough Capital Partners
Massachusetts
$2.59M -$112K -8,300 -4%
MAA
38
Managed Account Advisors
New Jersey
$2.52M +$9.95K +739 +0.4%
SC
39
Skylands Capital
Wisconsin
$2.28M +$1.03M +76,642 +79%
Charles Schwab
40
Charles Schwab
California
$2.23M +$46.7K +3,471 +2%
BIM
41
BlackRock Investment Management
Delaware
$2.21M +$13.3K +984 +0.6%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$2.14M
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$2.08M +$28.3K +2,100 +1%
Norges Bank
44
Norges Bank
Norway
$2.02M -$2.07M -153,904 -50%
CA
45
Continental Advisors
Utah
$1.81M
AllianceBernstein
46
AllianceBernstein
Tennessee
$1.59M -$10.7K -792 -0.6%
Deutsche Bank
47
Deutsche Bank
Germany
$1.59M +$1.05M +77,638 +177%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$1.49M +$16.8K +1,244 +1%
SGH
49
Sivik Global Healthcare
Connecticut
$1.31M
SCM
50
Sterling Capital Management
North Carolina
$1.21M

NXTM Hedge Fund Activity: Q3 2014 in Review

111 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q3 2014, worth a combined $721M — down 7% from $775M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of NXTM and 13 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 42 added.

The largest buyer was Deerfield Management, adding an estimated $16.7M. The largest seller was OrbiMed, exiting entirely with an estimated $11.4M sold.

  • 111 institutional investors held NxStage Medical Inc. (NXTM) as of Q3 2014, down from 115 in Q2 2014.
  • Funds reported $721M of NxStage Medical Inc. stock for Q3 2014, down 7% quarter-over-quarter.
  • 13 funds opened new NxStage Medical Inc. positions in Q3 2014 and 17 closed out, a net change of -4 holders.
  • The largest NxStage Medical Inc. buyer in Q3 2014 was Deerfield Management, an estimated $16.7M added.
  • The largest NxStage Medical Inc. seller in Q3 2014 was OrbiMed, an estimated $11.4M sold.

Based on aggregated 13F filings for Q3 2014.